🇺🇸 FDA
Patent

US 10207013

Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI

granted A61KA61K49/106A61K49/108

Quick answer

US patent 10207013 (Gadolinium-based contrast agents for sensitive detection of Zn2+ with MRI) held by The Board of Regents of the University of Texas System expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K49/106, A61K49/108